RxDoctor Payments Data

Truong Bao, MD

Internal Medicine · Rockville, MDNPI 1972553394

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 45 payments — averaging $37.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$310
  • Novartis$294
  • Esperion Therapeutics, Inc.$250
  • AbbVie$174
  • Acadia Pharmaceuticals Inc$158
  • Johnson & Johnson$118
  • plus $374 from 9 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$309,711
Medicare patients
551
Services billed
3,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$133,766
DescovyEmtricitabine/Tenofov Alafenam23$53,847
JulucaDolutegravir/Rilpivirine13$48,713
JardianceEmpagliflozin80$48,354
XifaxanRifaximin29$43,312
CaplytaLumateperone Tosylate22$38,706
TivicayDolutegravir Sodium15$33,438
TrulicityDulaglutide43$27,582
OzempicSemaglutide22$26,274
XareltoRivaroxaban43$24,972
JanuviaSitagliptin Phosphate28$19,332
RenvelaSevelamer Carbonate25$15,335
Incruse ElliptaUmeclidinium Bromide37$14,022
PrezistaDarunavir15$13,251
Atorvastatin Calcium640$12,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$133,766315 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$77$43,31229 claims
Johnson & JohnsonXarelto, Procrit$118$31,02364 claims
Lilly USA, LLCTrulicity$69$27,58243 claims
Novo NordiskOzempic$310$26,27422 claims
MerckJanuvia$19$19,33228 claims
NovartisEntresto$294$9,29119 claims
AbbVieRestasis$174$4,19020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →